The first and only therapy to delay onset of stage three Type 1 Diabetes is seeing the light

Teplizumab, the drug that demonstrated superiority when it comes to beta cell preservation. In conducted studies, the drug was successful in altering the progression of disease from stage 2 to 3 type 1 diabetes. A study showed that patients who were given Teplizumab also required less insulin unites, compared to others who were not administrated the drug.

Teplizumab is administrated as IV infusion once per day for 14 days in a row.

Finally, hope emerges with a potential treatment targeting the autoimmune etiology of type 1 diabetes for newly diagnosed children and adolescences.

References:

El-Nahas, R., Al-Aghbar, M., Herrero, L., Panhuys, N. & Espino-Guarch, M.(2023). Applications of genome-editing technologies for type 1 diabetes. International journal of molecular sciences, 25:1, pages 344.

Herold, K.C., Gitelman, S.E., Gottlieb, P.A., Knecht, L.A., Raymond, R., Ramos, E.L. (2023) Teplizumab: A disease-modifying therapy for type 1 diabetes that preserves β-cell function. Diabetes care, 1;46(10):1848-1856.

Ramos, E., Dayan, C., Chatenoud, L., Sumnik, Z., Simmons, K., Szypowska, A., Gitelman, S., Knecht, L., Niemoeller, E., Tian, W.  & Herold, K. (2023). Teplizumab and β-cell function in newly diagnosed Type 1 diabetes. The new England journal for medicine, 389:2151-2161